Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing

CHF 50 Million extension round co-led by Cormorant Asset Management, 
with participation from other existing investors

Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development

HORGEN, Switzerland, Jan. 09, 2025 (GLOBE NEWSWIRE) --  Numab Therapeutics AG (“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today the closing of an oversubscribed CHF 50 million (approximately USD 55 million) Series C extension, bringing the total Series C to CHF 180 million. The financing was co-led by Cormorant Asset Management, Forbion via its Forbion Growth Opportunities Fund, HBM Healthcare Investment, and Novo Holdings, with participation from other existing investors BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, and funds and accounts managed by BlackRock.

“We believe that Numab’s modular platform and engineering expertise in designing multi-specific antibodies with predictable stability, yield, and good CMC characteristics have significant advantages. We also believe multi-specific antibodies have the advantage of more efficient clinical trial design. We are excited to continue to support the team as they identify and pursue the best rational biological combinations for their platform”, said Bihua Chen, Founder and CEO of Cormorant Asset Management.

“Throughout 2024, we made tremendous progress with our pipeline and business development efforts, including the acquisition of Numab’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion”, said David Urech, Ph.D., Founder and Chief Executive Officer of Numab Therapeutics. “We are delighted to start the year by strengthening our financial position with the support of this strong group of investors who share our vision and conviction in the strength of Numab’s unique λ-CapTM and MATCHTM technology platforms and our regional partnering strategy that allows us to de-risk development of our proprietary pipeline.”

Proceeds from the financing will be used to accelerate and further advance Numab’s pipeline of clinical and pre-clinical best-in-class and first-in-class multi-specific antibodies in inflammation and oncology.

About Numab Therapeutics AG
Numab Therapeutics AG is a clinical-stage company developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-CapTM and MATCHTM puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of new and important medicines aimed to maximize patient benefits. Numab’s diverse research pipeline spans multiple therapeutic areas and creates the opportunity for the next generation of first-in-class and best-in-class medicines. Our lead asset, NM32, a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies, is currently in Phase 1 trial in patients with solid tumors. Numab’s partnerships with multiple leading pharma companies continue to validate the robust proprietary platform and development capabilities. For further information, visit https://www.numab.com

For further details, please contact:

Numab Therapeutics
David Urech
Chief Executive Officer
d.urech@numab.com

Investor Contact:
Patrick Till
Meru Advisors 
ptill@meruadvisors.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.